Kenneth Pittman
Long only, value, biotech, healthcare

Dynavax Is More Than Just HEPLISAV


I am a physician (currently practicing Child Psychiatry, also board certified in Pediatrics) and part-time investor. I invest in several biotech companies, including Dynavax Technologies (NASDAQ:DVAX), the main subject of this article. I look for the combination of good science, depth of pipeline, a market cap that appears undervalued, and a reasonably good technical stock profile. While Dynavax may have some concerns with regards to depth of pipeline and technical indicators, I believe that Dynavax represent an incredible value due to the near-certainty of HEPLISAV-B and the unrecognized potential of AZD1419.

Quarterly Release

On August 7th, 2014, Dynavax released Quarterly Results that included four main items. These were financial updates and an update on each of the...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details